Literature DB >> 25918138

New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.

Janus A J Haagensen1, Davide Verotta2, Liusheng Huang3, Alfred Spormann1, Katherine Yang4.   

Abstract

A new in vitro pharmacokinetic/pharmacodynamic simulator for bacterial biofilms utilizing flow cell technology and confocal laser scanning microscopy is described. The device has the ability to simulate the changing antibiotic concentrations in humans associated with intravenous dosing on bacterial biofilms grown under continuous culture conditions. The free drug concentrations of a single 2-g meropenem intravenous bolus dose and first-order elimination utilizing a half-life of 0.895 h (elimination rate constant, 0.776 h(-1)) were simulated. The antibacterial activity of meropenem against biofilms of Pseudomonas aeruginosa PAO1 and three clinical strains isolated from patients with cystic fibrosis was investigated. Additionally, the effect of meropenem on PAO1 biofilms cultured for 24 h versus that on biofilms cultured for 72 h was examined. Using confocal laser scanning microscopy, rapid biofilm killing was observed in the first hour of the dosing interval for all biofilms. However, for PAO1 biofilms cultured for 72 h, only bacterial subpopulations at the periphery of the biofilm were affected, with subpopulations at the substratum remaining viable, even at the conclusion of the dosing interval. The described model is a novel method to investigate antimicrobial killing of bacterial biofilms using human simulated concentrations.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25918138      PMCID: PMC4468651          DOI: 10.1128/AAC.05037-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

Review 1.  What in vitro models of infection can and cannot do.

Authors:  R L White
Journal:  Pharmacotherapy       Date:  2001-11       Impact factor: 4.705

Review 2.  Role of pharmacokinetics and pharmacodynamics: does the dose matter?

Authors:  A P MacGowan
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

Review 3.  Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models.

Authors:  Alasdair MacGowan; Karen Bowker
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

4.  Effect of flow regime on the architecture of a Pseudomonas fluorescens biofilm.

Authors:  Maria Olivia Pereira; Martin Kuehn; Stefan Wuertz; Thomas Neu; Luis F Melo
Journal:  Biotechnol Bioeng       Date:  2002-04-20       Impact factor: 4.530

5.  Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.

Authors:  Joseph L Kuti; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2003-10       Impact factor: 3.126

6.  Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  S Jalal; O Ciofu; N Hoiby; N Gotoh; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin.

Authors:  Marshall C Walters; Frank Roe; Amandine Bugnicourt; Michael J Franklin; Philip S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants.

Authors:  Mikkel Klausen; Arne Heydorn; Paula Ragas; Lotte Lambertsen; Anders Aaes-Jørgensen; Søren Molin; Tim Tolker-Nielsen
Journal:  Mol Microbiol       Date:  2003-06       Impact factor: 3.501

9.  Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms.

Authors:  Niels Bagge; Morten Hentzer; Jens Bo Andersen; Oana Ciofu; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 10.  Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

View more
  10 in total

1.  Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing Pseudomonas aeruginosa.

Authors:  Mathias Müsken; Vinay Pawar; Timo Schwebs; Heike Bähre; Sebastian Felgner; Siegfried Weiss; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

2.  Mathematical Modeling of Biofilm Structures Using COMSTAT Data.

Authors:  Davide Verotta; Janus Haagensen; Alfred M Spormann; Katherine Yang
Journal:  Comput Math Methods Med       Date:  2017-12-20       Impact factor: 2.238

3.  Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid.

Authors:  Liusheng Huang; Janus Anders Juul Haagensen; Davide Verotta; Vincent Cheah; Alfred M Spormann; Francesca Aweeka; Katherine Yang
Journal:  J Anal Methods Chem       Date:  2018-04-26       Impact factor: 2.193

4.  Mutations causing low level antibiotic resistance ensure bacterial survival in antibiotic-treated hosts.

Authors:  Jakob Frimodt-Møller; Elio Rossi; Janus Anders Juul Haagensen; Marilena Falcone; Søren Molin; Helle Krogh Johansen
Journal:  Sci Rep       Date:  2018-08-21       Impact factor: 4.379

5.  Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment.

Authors:  Jennifer A Bartell; David R Cameron; Biljana Mojsoska; Janus Anders Juul Haagensen; Tacjana Pressler; Lea M Sommer; Kim Lewis; Søren Molin; Helle Krogh Johansen
Journal:  PLoS Pathog       Date:  2020-12-14       Impact factor: 6.823

Review 6.  Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis.

Authors:  Renee N Ng; Anna S Tai; Barbara J Chang; Stephen M Stick; Anthony Kicic
Journal:  Front Microbiol       Date:  2021-01-11       Impact factor: 5.640

7.  Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.

Authors:  Janus Haagensen; Davide Verotta; Liusheng Huang; Joanne Engel; Alfred M Spormann; Katherine Yang
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

8.  Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm.

Authors:  Farhana Alam; Dominic Catlow; Alessandro Di Maio; Jessica M A Blair; Rebecca A Hall
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

9.  Pulse Dosing of Antibiotic Enhances Killing of a Staphylococcus aureus Biofilm.

Authors:  Kirsten J Meyer; Hannah B Taylor; Jazlyn Seidel; Michael F Gates; Kim Lewis
Journal:  Front Microbiol       Date:  2020-11-09       Impact factor: 5.640

10.  Biofilm and Planktonic Antibiotic Resistance in Patients With Acute Exacerbation of Chronic Rhinosinusitis.

Authors:  Henrique Augusto Cantareira Sabino; Fabiana Cardoso Pereira Valera; Denise Vieira Santos; Marina Zilio Fantucci; Carolina Carneiro Titoneli; Roberto Martinez; Wilma T Anselmo-Lima; Edwin Tamashiro
Journal:  Front Cell Infect Microbiol       Date:  2022-01-17       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.